17 research outputs found
Treatment with an Anti-CD44v10-Specific Antibody Inhibits the Onset of Alopecia Areata in C3H/HeJ Mice
A murine CD44v10-neutralizing antibody has been reported to impair delayed-type hypersensitivity reactions. Because alopecia areata is characterized by a delayed-type hypersensitivity-like T cell mediated immune response, we addressed the question whether an anti-CD44v10-antibody influences the onset of alopecia areata. Therefore, we used the C3H/HeJ mouse model with the induction of alopecia areata in unaffected mice by the grafting of lesional alopecia areata mouse skin. Six grafted mice were injected (intraperitoneally) with anti-CD44v10, six grafted mice with anti-CD44standard, and six with phosphate-buffered saline only. After 11 wk phosphate-buffered saline injected animals on average had developed alopecia areata on 36.8% of their body. The onset of hair loss was slightly delayed and its extent reduced to 17.2% of their body in anti-CD44standard-treated mice. By contrast, five of six anti-CD44v10-treated mice did not show any hair loss and one mouse developed alopecia areata on only 1% of the body. Immunohistochemical examination revealed a marked reduction of perifollicular CD8+ lymphocytes and, to a lesser degree, CD4+ cells as well as a decreased expression of major histocompatibility complex class I on hair follicle epithelium in anti-CD44v10-treated mice as compared with phosphate-buffered saline or anti-CD44 standard-treated mice. Our data show that anti-CD44v10 is able to inhibit the onset of alopecia areata in C3H/HeJ mice. This might be accomplished by an anti-CD44v10-triggered impairment of immune cell homing (e.g., CD8+ T cells), resulting in a decrease of their number in target tissues
Priority-setting for achieving universal health coverage.
Governments in low- and middle-income countries are legitimizing the implementation of universal health coverage (UHC), following a United Nation's resolution on UHC in 2012 and its reinforcement in the sustainable development goals set in 2015. UHC will differ in each country depending on country contexts and needs, as well as demand and supply in health care. Therefore, fundamental issues such as objectives, users and cost-effectiveness of UHC have been raised by policy-makers and stakeholders. While priority-setting is done on a daily basis by health authorities - implicitly or explicitly - it has not been made clear how priority-setting for UHC should be conducted. We provide justification for explicit health priority-setting and guidance to countries on how to set priorities for UHC
Multiple Interfaces of Big Pharma and the Change of Global Health Governance in the Face of HIV/AIDS
In-Orbit Performance of the GRACE Follow-on Laser Ranging Interferometer
The Laser Ranging Interferometer (LRI) instrument on the Gravity Recovery and Climate Experiment (GRACE) Follow-On mission has provided the first laser interferometric range measurements between remote spacecraft, separated by approximately 220 km. Autonomous controls that lock the laser frequency to a cavity reference and establish the 5 degrees of freedom two-way laser link between remote spacecraft succeeded on the first attempt. Active beam pointing based on differential wave front sensing compensates spacecraft attitude fluctuations. The LRI has operated continuously without breaks in phase tracking for more than 50 days, and has shown biased range measurements similar to the primary ranging instrument based on microwaves, but with much less noise at a level of 1 nm/Hz at Fourier frequencies above 100 mHz. © 2019 authors. Published by the American Physical Society
Purchasing Pharmaceuticals in \u3cem\u3eSpending Wisely: Buying Health Services for the Poor\u3c/em\u3e
Pharmaceuticals are a critical input to the proper functioning of the health services. Most curative and many preventive health services depend on pharmaceuticals. Patients perceive availability of pharmaceuticals in a facility as an indicator of the quality of health services, and drug availability helps explain overall utilization of health services. Despite significant progress in increasing the number of people with access to essential medicine over the past decades, a substantial share of the world’s population (more than a third worldwide and more than half in the poorest parts of Africa and Asia) still lack access to reliable supplies of essential medicines (World Health Organization [WHO] 2000). Many factors influence whether poor people can obtain affordable essential drugs of standard quality. Increased access to drugs depends on an efficient resource allocation and purchasing (RAP) system including rational selection and use of medicines, adequate and sustainable financing, affordable prices, and reliable health care and drug supply systems. This chapter is based on literature found by systematic search of published literature, particularly in Africa and Asia. Search criteria included pharmaceuticals/ drugs and developing countries combined with key parameters regarding RAP (Enemark, Alban, and Seoane-Vazquez 2004).https://digitalcommons.chapman.edu/pharmacy_books/1020/thumbnail.jp